Literature DB >> 24388316

Prolonged remission of juvenile-onset respiratory papillomatosis: a post-expositional role of the tetravalent anti-HPV vaccine?

Laurent Yi1, Bernard Vaudaux1, Kishore Sandu2, Lluís Nisa3.   

Abstract

Juvenile-onset recurrent respiratory papillomatosis (JORRP) is an HPV-related neoplasm affecting primarily the larynx. JORRP often requires repeated surgical debridement, which yield variable but generally moderate remission periods. We report the case of a 6-year-old boy with severe course JORRP since the age of 2, requiring tracheostomy, that underwent prolonged remission and was decannulated some months after administration of the HPV vaccine. The post-exposure use for the anti-HPV vaccine in JORRP is a topic of capital interest but still poorly characterized. Some published cases suggest a potential post-exposure role of the vaccine in JORRP, but prospective multicentric trials are still needed.
Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Anti-HPV vaccine; Juvenile-onset recurrent respiratory papillomatosis

Mesh:

Substances:

Year:  2013        PMID: 24388316     DOI: 10.1016/j.ijporl.2013.12.013

Source DB:  PubMed          Journal:  Int J Pediatr Otorhinolaryngol        ISSN: 0165-5876            Impact factor:   1.675


  2 in total

1.  HPV Type 6 and 18 Coinfection in a Case of Adult-Onset Laryngeal Papillomatosis: Immunization with Gardasil.

Authors:  Virginia Fancello; Andrea Melis; Andrea Fausto Piana; Paolo Castiglia; Andrea Cossu; Giovanni Sotgiu; Corrado Bozzo; Emma Victoria King; Francesco Meloni
Journal:  Case Rep Otolaryngol       Date:  2015-11-29

Review 2.  Multidisciplinary, evidence-based consensus guidelines for human papillomavirus (HPV) vaccination in high-risk populations, Spain, 2016.

Authors:  Xavier Martínez-Gómez; Adrian Curran; Magda Campins; Laia Alemany; José Ángel Rodrigo-Pendás; Natalia Borruel; Xavier Castellsagué; Cristina Díaz-de-Heredia; Fernando A Moraga-Llop; Marta Del Pino; Aureli Torné
Journal:  Euro Surveill       Date:  2019-02
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.